KOPRAN vs SUPRIYA: Stock Comparison

Kopran Limited vs Supriya Lifescience Limited

Live data: 29 May 2026, 4:01 PM IST • Source: NSE and company filings

Supriya Lifescience Limited is the larger company by market capitalisation. Kopran Limited shows a higher dividend yield, while Supriya Lifescience Limited shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Kopran Limited and Supriya Lifescience Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KOPRAN is more favourable on 2 of 13 scored metrics and SUPRIYA on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUPRIYA is the larger company
₹6,704 Cr vs ₹942 Cr
P/E Ratio
SUPRIYA has a lower P/E
33.24x vs 38.28x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 5.8x
EPS
SUPRIYA has higher earnings per share
₹25.94 vs ₹3.41
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0.11%
Revenue Growth (TTM YoY)
SUPRIYA has faster revenue growth
50.2% vs -3.66%
EPS Growth (TTM YoY)
SUPRIYA has faster EPS growth
46.7% vs -71.88%
Qtr Sales Growth
SUPRIYA has stronger quarterly sales growth
50.2% vs -3.03%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANSUPRIYA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANSUPRIYA
Live Price₹206.27₹839.5
Day Change6.56%-2.79%
Volume38.55 L1.76 L
52-Week High₹219₹1,085
52-Week Low₹107₹545.5
Distance from 52W High-5.81%-22.63%

Valuation

MetricKOPRANSUPRIYA
Market Cap₹942 Cr₹6,704 Cr
P/E Ratio38.28x33.24x
P/B Ratio1.86x5.8x
EPS₹3.41₹25.94
Book Value₹107.35₹148.77
Dividend Yield1.59%0.11%

Growth

MetricKOPRANSUPRIYA
Revenue Growth (TTM YoY)-3.66%50.2%
EPS Growth (TTM YoY)-71.88%46.7%
Qtr Sales Growth-3.03%50.2%
Qtr Profit Growth-32.9%47.3%

Profitability & Leverage

MetricKOPRANSUPRIYA
ROE4.85%19.1%
ROCE9.75%25.1%
Net Margin3.78%25.26%
Operating Margin6.58%35.5%
Debt to Equity0.29x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANSUPRIYA
Promoter Holding44.42%68.3%
FII Holding0.51% 0.06 pp5.16% 0.04 pp
DII Holding0%5.7% 0.69 pp
Public Holding55.06% 0.06 pp20.84% 0.66 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Kopran Limited and Supriya Lifescience Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.